abstract |
Bacillus Calmette-Guerin (BCG) administration plays a central role in managing carcinoma in situ of the bladder. Unfortunately, recurrence or progression of disease is seen in up to 30% of treated patients. Disclosed herein is a method for predicting responsiveness to treatment with BCG based on BCG internalization by bladder cancer cells, the presence or absence of mutations associated with BCG uptake or a combination thereof. |